Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:KROSNASDAQ:ORKANASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.32-4.5%$6.24$5.14▼$11.16$409.71M0.872.94 million shs1.33 million shsKROSKeros Therapeutics$10.79-1.8%$11.15$9.78▼$72.37$437.66M1.39696,696 shs277,817 shsORKAOruka Therapeutics$12.50+4.6%$11.60$9.44▼$31.13$468.01M0.67214,672 shs136,716 shsVXRTVaxart$0.42-7.8%$0.62$0.42▼$1.34$95.82M1.692.37 million shs1.92 million shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-4.49%-8.17%-10.44%-30.64%-40.16%KROSKeros Therapeutics-1.82%-3.83%-1.37%-34.29%-83.31%ORKAOruka Therapeutics+4.60%+3.31%+18.71%-34.25%+1,249,999,900.00%VXRTVaxart-7.83%-18.39%-19.48%-42.36%-67.35%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.6865 of 5 stars3.41.00.00.03.43.30.6KROSKeros Therapeutics3.6342 of 5 stars4.33.00.00.02.53.30.6ORKAOruka Therapeutics3.174 of 5 stars3.60.00.00.02.74.20.6VXRTVaxart2.0346 of 5 stars3.53.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.89Moderate Buy$20.83291.60% UpsideKROSKeros Therapeutics 2.57Moderate Buy$42.33292.34% UpsideORKAOruka Therapeutics 3.22Buy$39.86218.86% UpsideVXRTVaxart 3.00Buy$3.00612.25% UpsideCurrent Analyst Ratings BreakdownLatest VXRT, ALT, KROS, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025VXRTVaxartB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $2.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/7/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.003/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/28/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform2/27/2025KROSKeros TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $26.002/27/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $40.002/7/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.002/5/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/4/2025ORKAOruka TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K20,485.72N/AN/A$2.75 per share1.93KROSKeros Therapeutics$3.55M123.29N/AN/A$11.09 per share0.97ORKAOruka TherapeuticsN/AN/AN/AN/AN/AN/AVXRTVaxart$28.70M3.34N/AN/A$0.38 per share1.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)KROSKeros Therapeutics-$152.99M-$5.01N/AN/AN/A-27,890.94%-41.74%-38.42%5/6/2025 (Estimated)ORKAOruka Therapeutics-$5.34M-$5.79N/AN/AN/AN/A-24.96%-21.22%4/24/2025 (Estimated)VXRTVaxart-$82.46M-$0.34N/AN/AN/A-431.61%-110.46%-62.78%5/12/2025 (Estimated)Latest VXRT, ALT, KROS, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025N/AORKAOruka Therapeutics-$0.57N/AN/AN/AN/AN/A3/20/2025Q4 2024VXRTVaxart-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million3/6/2025Q4 2024ORKAOruka Therapeutics-$0.68-$0.49+$0.19-$0.49N/AN/A2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million2/26/2025Q4 2024KROSKeros Therapeutics-$1.36-$1.14+$0.22-$1.14$37.32 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87KROSKeros TherapeuticsN/A19.0319.03ORKAOruka TherapeuticsN/A22.8922.89VXRTVaxartN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%KROSKeros Therapeutics71.56%ORKAOruka Therapeutics56.44%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%KROSKeros Therapeutics22.90%ORKAOruka Therapeutics22.67%VXRTVaxart2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableKROSKeros Therapeutics10040.56 million31.23 millionOptionableORKAOruka TherapeuticsN/A37.44 million27.07 millionN/AVXRTVaxart120227.48 million221.57 millionOptionableVXRT, ALT, KROS, and ORKA HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. RileyMarch 28 at 1:38 PM | marketbeat.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27 at 10:40 PM | markets.businessinsider.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27 at 8:00 AM | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPSMarch 21, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Issues Earnings ResultsMarch 21, 2025 | marketbeat.comVaxart, Inc. (NASDAQ:VXRT) Sees Significant Growth in Short InterestMarch 21, 2025 | americanbankingnews.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comVAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue EstimatesMarch 20, 2025 | zacks.comVaxart Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Short Interest UpdateMarch 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?March 14, 2025 | marketbeat.comVaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20March 14, 2025 | markets.businessinsider.comVaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025March 13, 2025 | quiverquant.comVaxart announces trial initiation of norovirus oral pill vaccine candidateMarch 11, 2025 | markets.businessinsider.comVaxart, Inc. Launches Phase 1 Clinical Trial for Second-Generation Oral Norovirus Vaccine ConstructsMarch 11, 2025 | quiverquant.comVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateMarch 11, 2025 | globenewswire.comVaxart (VXRT) to Release Earnings on ThursdayMarch 11, 2025 | marketbeat.comVaxart (VXRT) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comVaxart announces norovirus vaccine candidate trial data publishedMarch 5, 2025 | markets.businessinsider.comVaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly AdultsMarch 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsCybersecurity Stocks Surge as $32B Deal Reshapes the IndustryBy Gabriel Osorio-Mazilli | March 21, 2025View Cybersecurity Stocks Surge as $32B Deal Reshapes the IndustryCould Palantir’s R1 Deal Be the Catalyst for a Stock Surge?By Chris Markoch | March 21, 2025View Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?3 Dividend Picks Standing Strong as Bond Yields FallBy Gabriel Osorio-Mazilli | March 12, 2025View 3 Dividend Picks Standing Strong as Bond Yields Fall3 ETFs to Ride the VIX Surge During Market VolatilityBy Nathan Reiff | March 23, 2025View 3 ETFs to Ride the VIX Surge During Market VolatilityVXRT, ALT, KROS, and ORKA Company DescriptionsAltimmune NASDAQ:ALT$5.32 -0.25 (-4.49%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$5.33 +0.01 (+0.11%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Keros Therapeutics NASDAQ:KROS$10.79 -0.20 (-1.82%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$10.80 +0.01 (+0.05%) As of 03/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Oruka Therapeutics NASDAQ:ORKA$12.50 +0.55 (+4.60%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$12.44 -0.06 (-0.52%) As of 03/28/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Vaxart NASDAQ:VXRT$0.42 -0.04 (-7.83%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.43 +0.01 (+1.38%) As of 03/28/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
